Type 1 diabetes: Victoza and Belviq/BelPhen
Victoza $2500-$3200/month (niche market), Belviq $150-$200/month (wide audience)
Contrave: 4000 siezures/ million users with potential for 40 deaths. (will FDA really approve this?)
Vivus: dead! put a fork in her, management left months ago with the booty!
This from a guy who predicted blockbuster status for Belviq.
I think you meant type 2 diabetes.
Contrave potentially kills 40 out of a million users? FDA says screw Americans and potentially approves this? Heads should roll at the FDA. Will be a lawyers field day/money pot of gold with all the lawsuits!
As of 2012, Caduet (Lipitor + Norvasc) sold at an annual rate of $338 mil...hardly a huge success. Most are cost conscious and will not pay a premium for one-pill convenience IMO.
In time I am sure
Sentiment: Strong Buy